COMPUGEN LTD business relationships
Companies named in COMPUGEN LTD’s 20-F filed 2026-03-02, and public companies whose annual reports name COMPUGEN LTD. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 62 / 100 Top 2% in its category
- Agent readiness
- 40 / 100
- AI adoption
- 0 / 100
Named in COMPUGEN LTD’s annual report 12
“On December 16, 2025, we amended the license agreement and sold to AstraZeneca a portion” SEC filing
“GS-0321 (previously COM503) is licensed to Gilead and is” SEC filing
“In connection with such license agreement, AstraZeneca” SEC filing
“Pursuant to the license agreement, Gilead paid us a $60 million upfront license payment” SEC filing
“as well as licensing agreements with Merck (MSD), Genentech and others.” SEC filing
“Rilvegostomig is currently being evaluated by our collaborator, AstraZeneca,in multiple” SEC filing
“of the termination of the collaboration agreement with Bayer in 2023 was extinguishing our potential to achieve future revenues from such” SEC filing
“Strategy and Partnerships - Gilead License", and "Item 4.” SEC filing
“are only responsible for Phase 1 clinical development) and rilvegostomig which is developed by AstraZeneca, is dependent upon several” SEC filing
“The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct.” SEC filing
“from China's 3SBio, and a collaboration between GSK and Hengrui Pharmaceuticals valued up to $12 billion, demonstrating that” SEC filing
“as well as licensing agreements with Merck (MSD), Genentech and others.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.